AR055606A1 - Derivados de benzoquinazolina - Google Patents
Derivados de benzoquinazolinaInfo
- Publication number
- AR055606A1 AR055606A1 ARP060103529A ARP060103529A AR055606A1 AR 055606 A1 AR055606 A1 AR 055606A1 AR P060103529 A ARP060103529 A AR P060103529A AR P060103529 A ARP060103529 A AR P060103529A AR 055606 A1 AR055606 A1 AR 055606A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkyloxy
- amino
- sulfonyl
- hydroxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composicion farmacéutica, proceso y uso para prevenir o tratar condiciones oseas. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable o éster de profármaco del mismo, en donde: Q es CH o N; R2 es alquilo C1-4; Y se selecciona a partir del grupo que consiste en R5-O-, alquilo C1-4, alquenilo C1-4, alquinilo C1-4, R5-NH-; en donde R5 es alquilo C1-4, alquenilo C1-4, alquinilo C1-4; X se selecciona a partir del grupo que consiste en arilo, heteroarilo, alquilo C1-10, alquiloxilo C1-10, ciclo-alquilo, heterociclo-alquilo, aril-alquilo C1-4, heteroaril-alquilo C1-4, cicloalquil-alquilo C1-4, heterocicloalquil-alquilo C1-4, aril-amino, heteroaril-amino, aril-alquilo C1-4-amino, heteroaril-alquilo C1-4-amino, alquilo C1-6-amino, dialquilo C1-6-amino, ariloxilo, heteroariloxilo, aril-alquiloxilo C1-4, heteroaril-alquiloxilo C1-4, cicloalquil-alquilo C1-4-amino, heterocicloalquil-alquilo C1-4-amino, cicloalquil-alquiloxilo C1-4, o heterociclo-alquil- alquiloxilo C1-4, cada uno de los cuales está opcionalmente sustituido una o más veces; seleccionándose el sustituyente o los sustituyentes opcionales sobre X independientemente a partir del grupo que consiste en halogeno, ciano, trifluoro-metilo, nitro, hidroxilo, (alquilo C1-4, alquiloxilo C1-4, amino, sulfanilo, sulfonilo, amino, oxicarbonilo, hidroxilo, sulfinilo, amino-sulfonilo, sulfonil-amino, carbonilo, carboniloxilo, carbonil-amino, carboxilo, acilo, acilamino, o carbamoílo) opcionalmente sustituidos; seleccionándose el sustituyente o los sustituyentes opcionales a partir de alquilo C1-6, alquiloxilo C1-6, carboxilo, hidroxilo, hidroxi-alquilo C1-4, cada uno de los cuales a su vez puede estar opcionalmente sustituido por alquiloxilo C1-6, alquilo C1-6, alquilo fluorado C1-3, alquiloxilo C1-6, carboxilo, hidroxilo, hidroxi-alquilo C1-4, halogeno, ciano, nitro; R3 y R4 cada uno representa uno o más sustituyentes independientemente seleccionados a partir de: H, halogeno, alquilo C1-4, alquiloxilo C1-4, CF3; seleccionándose el sustituyente o los sustituyentes opcionales sobre R3 o R4 independientemente a partir del grupo que consiste en alquilo C1-4, halogeno, alquiloxilo C1-4, ciano, sulfanilo, sulfonilo, amino, oxicarbonilo, hidroxilo, los cuales a su vez pueden estar opcionalmente sustituidos una o más veces por alquilo C1-4, halogeno, alquiloxilo C1-4, ciano, sulfanilo, sulfonilo, amino, oxicarbonilo, o hidroxilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516723.4A GB0516723D0 (en) | 2005-08-15 | 2005-08-15 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055606A1 true AR055606A1 (es) | 2007-08-29 |
Family
ID=35098331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103529A AR055606A1 (es) | 2005-08-15 | 2006-08-11 | Derivados de benzoquinazolina |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20100166765A1 (es) |
| EP (1) | EP1917246B1 (es) |
| JP (1) | JP2009505984A (es) |
| KR (1) | KR20080043778A (es) |
| CN (1) | CN101233112A (es) |
| AR (1) | AR055606A1 (es) |
| AT (1) | ATE448206T1 (es) |
| AU (1) | AU2006281627B2 (es) |
| BR (1) | BRPI0614544A2 (es) |
| CA (1) | CA2619249A1 (es) |
| CY (1) | CY1110247T1 (es) |
| DE (1) | DE602006010401D1 (es) |
| DK (1) | DK1917246T3 (es) |
| EC (1) | ECSP088184A (es) |
| ES (1) | ES2336484T3 (es) |
| GB (1) | GB0516723D0 (es) |
| GT (1) | GT200600372A (es) |
| HK (1) | HK1117154A1 (es) |
| HR (1) | HRP20100072T1 (es) |
| IL (1) | IL188922A0 (es) |
| JO (1) | JO2585B1 (es) |
| MA (1) | MA29742B1 (es) |
| MX (1) | MX2008002163A (es) |
| NO (1) | NO20081315L (es) |
| NZ (1) | NZ565605A (es) |
| PE (2) | PE20100239A1 (es) |
| PL (1) | PL1917246T3 (es) |
| PT (1) | PT1917246E (es) |
| RU (1) | RU2416602C2 (es) |
| SA (1) | SA06270266B1 (es) |
| SI (1) | SI1917246T1 (es) |
| TN (1) | TNSN08070A1 (es) |
| TW (1) | TW200740758A (es) |
| WO (1) | WO2007020046A1 (es) |
| ZA (1) | ZA200800434B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
| PT2004654E (pt) | 2006-04-04 | 2013-08-27 | Univ California | Derivados de pirazolopirimidina para utilização como antagonistas da quinase |
| EP1956019A1 (en) * | 2007-01-22 | 2008-08-13 | Novartis AG | Benzoquinazoline derivatives |
| AR068124A1 (es) | 2007-08-30 | 2009-11-04 | Novartis Ag | Derivados de fenil - isoquinolina y fenil - quinazolina |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン， エルエルシー | 特定の化学的実体、組成物および方法 |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| MX2011000216A (es) | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010042489A2 (en) * | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| NZ593996A (en) * | 2009-01-19 | 2012-10-26 | Daiichi Sankyo Co Ltd | Naphthyridine-carboxamide and isoquinoline-carboxamide derivatives for treating osteoporosis |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| JP5654246B2 (ja) * | 2010-03-03 | 2015-01-14 | 一般社団法人ファルマバレープロジェクト支援機構 | キナゾリン化合物を有効成分とする医薬組成物 |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| CA2824197C (en) | 2011-01-10 | 2020-02-25 | Michael Martin | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| US8993555B2 (en) | 2012-12-21 | 2015-03-31 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| MX2016004340A (es) | 2013-10-04 | 2016-08-08 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PT3119397T (pt) | 2014-03-19 | 2022-04-11 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX2018016227A (es) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525595A1 (fr) * | 1982-04-27 | 1983-10-28 | Pharmuka Lab | Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments |
| JPH0769890A (ja) * | 1993-06-29 | 1995-03-14 | Takeda Chem Ind Ltd | キノリンまたはキナゾリン誘導体を含んでなる医薬組成物 |
| US5958954A (en) * | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| AR038658A1 (es) * | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| GB0230015D0 (en) * | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
-
2005
- 2005-08-15 GB GBGB0516723.4A patent/GB0516723D0/en not_active Ceased
-
2006
- 2006-08-09 SA SA6270266A patent/SA06270266B1/ar unknown
- 2006-08-11 AR ARP060103529A patent/AR055606A1/es not_active Application Discontinuation
- 2006-08-11 GT GT200600372A patent/GT200600372A/es unknown
- 2006-08-14 CA CA002619249A patent/CA2619249A1/en not_active Abandoned
- 2006-08-14 CN CNA2006800283555A patent/CN101233112A/zh active Pending
- 2006-08-14 AT AT06776845T patent/ATE448206T1/de active
- 2006-08-14 DK DK06776845.7T patent/DK1917246T3/da active
- 2006-08-14 PL PL06776845T patent/PL1917246T3/pl unknown
- 2006-08-14 RU RU2008109654/04A patent/RU2416602C2/ru not_active IP Right Cessation
- 2006-08-14 SI SI200630550T patent/SI1917246T1/sl unknown
- 2006-08-14 JP JP2008526424A patent/JP2009505984A/ja active Pending
- 2006-08-14 PT PT06776845T patent/PT1917246E/pt unknown
- 2006-08-14 TW TW095129808A patent/TW200740758A/zh unknown
- 2006-08-14 PE PE2010000013A patent/PE20100239A1/es not_active Application Discontinuation
- 2006-08-14 US US12/063,526 patent/US20100166765A1/en not_active Abandoned
- 2006-08-14 MX MX2008002163A patent/MX2008002163A/es active IP Right Grant
- 2006-08-14 ES ES06776845T patent/ES2336484T3/es active Active
- 2006-08-14 PE PE2006000987A patent/PE20070419A1/es not_active Application Discontinuation
- 2006-08-14 DE DE602006010401T patent/DE602006010401D1/de active Active
- 2006-08-14 JO JO2006270A patent/JO2585B1/en active
- 2006-08-14 WO PCT/EP2006/008036 patent/WO2007020046A1/en active Application Filing
- 2006-08-14 KR KR1020087003565A patent/KR20080043778A/ko not_active Application Discontinuation
- 2006-08-14 NZ NZ565605A patent/NZ565605A/en not_active IP Right Cessation
- 2006-08-14 BR BRPI0614544-2A patent/BRPI0614544A2/pt not_active IP Right Cessation
- 2006-08-14 EP EP06776845A patent/EP1917246B1/en active Active
- 2006-08-14 AU AU2006281627A patent/AU2006281627B2/en not_active Ceased
-
2008
- 2008-01-15 ZA ZA200800434A patent/ZA200800434B/xx unknown
- 2008-01-21 IL IL188922A patent/IL188922A0/en unknown
- 2008-02-13 MA MA30652A patent/MA29742B1/fr unknown
- 2008-02-14 EC EC2008008184A patent/ECSP088184A/es unknown
- 2008-02-14 TN TNP2008000070A patent/TNSN08070A1/en unknown
- 2008-03-12 NO NO20081315A patent/NO20081315L/no not_active Application Discontinuation
- 2008-07-22 HK HK08108070.8A patent/HK1117154A1/xx not_active IP Right Cessation
-
2010
- 2010-02-09 HR HR20100072T patent/HRP20100072T1/hr unknown
- 2010-02-10 CY CY20101100130T patent/CY1110247T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055606A1 (es) | Derivados de benzoquinazolina | |
| ES2512491T3 (es) | Derivados de la piridina pirazolo como inhibidores de la NADPH oxidasa | |
| AR125414A2 (es) | INHIBIDORES DE INTEGRINA avb6 | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
| NO20090835L (no) | Nye HIV-reverstranskriptaseinhibitorer | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
| AR061374A1 (es) | Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos | |
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| AR049861A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los co0ntienen. | |
| AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
| AR065425A1 (es) | Derivados fungicidas de n-(3-fenilpropil)-carboxamida | |
| AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| UY32004A (es) | Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |